Analysts Admire Argenx's Vyvgart Launch
Pipeline-In-A-Product Off To Strong Start
Executive Summary
The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.
You may also be interested in...
AstraZeneca’s Ultomiris Nears EU Green Light For NMOSD
The UK major’s long-acting C5 inhibitor is nearing EU approval for the debilitating rare disease as the company gears up for emerging competition and loss of exclusivity for its older drug Soliris.
Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success
Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren told In Vivo sister publication Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.
Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success
Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren tells Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.